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To evaluate the prevalence of gestational diabetes mellitus (GDM) in women with polycystic 
ovary syndrome (PCOS) and to investigate the efficacy of Metformin in reduction of 
gestational diabetes in women with polycystic ovary syndrome. 
1.2 Design 
Review of literature on prevalence of gestational diabetes and evaluation of efficacy of 
Metformin in reducing the prevalence of gestational diabetes in women with polycystic 
ovary syndrome. 
1.3 Setting 
Reproductive Endocrinology section of Department of Obstetrics and Gynecology of Aga 
Khan University Hospital Karachi Pakistan. 
1.4 Patient(s) 
Women with PCOS and gestational diabetes  
1.5 Intervention(s) 
Literature search in the electronic databases MEDLINE, study of the references of all 
relevant trials or reviews, and manual search of the abstracts from the major meetings in the 
field of human reproduction. 
1.6 Main outcome measure 
Odds Ratio( OR) for the occurrence of gestational Diabetes. 
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1.7 Result(s) 
Women with PCOS demonstrated a significantly higher risk for the development of GDM as 
compared with women without PCOS 
1.8 Description 
The Polycystic Ovarian Syndrome (PCOS) is a common endocrinopathy, affecting 
approximately 5–10% of women of reproductive age. In its classical form, the syndrome is 
characterized by oligo- or anovulation, biochemical or clinical hyperandrogenismand 
polycystic ovarian morphology on ultrasonography. Although much remains unknown 
regarding the underlying path physiology of PCOS, a form of insulin resistance intrinsic to 
the syndromeappears to play a central role in its development. Among many women with 
PCOS, the observed insulin resistance is partially explained by excess adiposity; however, it 
is increasingly recognized that even lean women with PCOS have increased insulin 
resistance compared with normal controls. Affected women have an increased risk of 
glucose intolerance, gestational diabetes mellitus (GDM) and type 2 diabetes. Some, studies 
suggest the risk of GDM is higher among PCOS versus non-PCOS women, and several 
studies note an increased prevalence of polycystic ovarian morphology and symptoms in 
women with prior GDM.  
Insulin resistance is defined as the decreased ability of insulin to stimulate glucose disposal 
into target tissues, or a reduced glucose response to a given amount of insulin. Chronic 
hyperinsulinemia is a compensatory response to this target tissue resistance. Several 
mechanisms have been suggested to explain insulin resistance, including peripheral target 
tissue resistance, decreased hepatic clearance, or increased pancreatic sensitivity. The 
peripheral insulin resistance in PCOS is uniquely due to a defect beyond the activation of 
the receptor kinase, namely, reduced tyrosine autophosphorylation of the insulin receptor 
and enhances the expression of hyperandrogenism by its inhibitory effect on hepatic sex 
hormone binding globulin (SHBG) production thereby increasing the bioavailability of 
androgens which leads to metabolic and obstetrical complications. Significant metabolic 
burden of insulin resistance is seen in women with PCOS, affected women may have an 
increased risk of impaired glucose tolerance (IGT), GDM and type 2 diabetes mellitus (DM).  
In pregnant women with PCOS, the increasing tissue resistance to insulin, mainly caused by 
placental hormones, adds on the preexisting state of insulin resistance, which may 
accompany the syndrome. This pathogenic mechanism could lead to hyperglycemia, 
reflected in a higher incidence of GDM. However, studies on GDM prevalence in women 
with PCOS gave conflicting results; considering the heterogeneity of PCOS and the diversity 
in methodology of screening and diagnosing GDM, these results should have been 
expected. 
A method of combining the results of the studies addressing the risk of Incidence of GDM in 
women with PCOS was one of the endpoints in addressing pregnancy complications in 
women with PCOS. Women with PCOS demonstrated a significantly higher chance of the 
development of GDM, though with significant statistical heterogeneity among the studies. 
This heterogeneity was not further analyzed or accounted for. To examine whether women 
with PCOS have a greater risk for the development of GDM than women without PCOS, we 
performed a review of literature and analysis of available trial 
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2. PCOS, Gestational Diabetes Mellitus (GDM) and diabetes  
It has been recognized that women with PCOS have a higher risk for developing type 2 
diabetes mellitus and gestational diabetes .In a retrospective cohort follow-up of patients 
with PCOS, the prevalence of diabetes mellitus was 7-fold higher than in controls. 
Gestational diabetes is defined as impaired glucose tolerance diagnosed for the first time 
during pregnancy, occurs in 2–5% of pregnancies and usually resolves at the end of 
gestation. However, between one half and one third of women with gestational diabetes 
may develop diabetes 2–11 years post-partum. Different studies have shown that women 
with PCOS have a higher risk for the development of gestational diabetes in relation to 
insulin resistance . Moreover, other authors have demonstrated a high incidence of 
polycystic ovaries in women with history of gestational diabetes Gestational diabetes is 
associated with a high neonatal morbidity and given that patients with PCOS have a high 
prevalence of gestational diabetes, these women should be considered to be at risk. 
Therefore, preventive measures before pregnancy to minimize neonatal morbidity should be 
recommended, including dietary advice and physical exercise as well as to indicate insulin-
sensitizing treatments before; and during pregnancy. 
In reproductive age, the prevalence of type 2 diabetes mellitus is estimated between 1.7 and 
6.1%. This prevalence would be expected to be from 5–10-fold higher in women with PCOS. 
On the other hand, PCOS may be considered a pre-diabetic state with a prevalence of 
impaired glucose tolerance of 31–35% and a prevalence of type 2 diabetes of 7.5–10%. 
Impaired glucose tolerance is characterized by moderate increases of fasting glucose levels 
that may precede diabetes. Women with impaired glucose tolerance are asymptomatic; 
therefore, an oral glucose tolerance test is required for diagnosis. Conversion of impaired 
glucose tolerance to frank diabetes in women with PCOS is 5–10 times more frequent 
compared with normal women The mean age at diagnosis of type 2 diabetes mellitus in 
patients with PCOS (30–40 years of age) is lower than in normal women (60–70 years of age) 
Additionally, a family history of diabetes and the presence of obesity are important 
predictors for the development of type 2 diabetes mellitus. 
The diagnostic criteria of diabetes based on the 1999 World Health Organization definition 
and the 1997 recommendations of the Expert Committee of the ADA is a fasting glucose 
level ≥126mg/dl (7mmol/l) or oral glucose tolerance test (2h plasma glucose after 75g oral 
glucose challenge) ≥200mg/dl (11.1mmol/l). Diagnostic criteria of impaired glucose 
tolerance include normal fasting glucose levels (<126mg/dl) in association with oral glucose 
tolerance test ≥140 and <200mg/dl (7.8–11.1mmol/l). Normal baseline plasma glucose levels 
are 110mg/dl (6.1mmol/l). The principal difference between the 1997 ADA criteria and the 
1999 WHO criteria is that the ADA criteria discourage the use of the oral glucose tolerance 
test as a routine diagnostic tool whereas the WHO criteria do not. However, it seems that 
the WHO criteria are more adequate for the diagnosis of diabetes in women with PCOS 
tolerance test . 
These data indicate that women with PCOS are at high risk for long-term development of 
type 2 diabetes mellitus, and support the importance of an early diagnosis and treatment of 
insulin resistance to help reduce the incidence and severity of diabetes, dyslipidemia, 
hypertension and cardiovascular disease 
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3. Review of role of insulin sensitizing agents (metformin) in prevention of 
gestational diabetes in women with pcos 
A major change in the treatment of PCOS was initiated by the understanding that many 
women with this disorder compensate insulin resistance with a period of hyper secretion 
of insulin by the pancreatic beta cell. This understanding has been incorporated into the 
framework of PCOS treatments through the beneficial effects of insulin-sensitizing 
treatments on the PCOS phenotype Agents that improve insulin sensitivity (and lower 
circulating insulin levels) include metformin as well as thiazolidinediones, pioglitazone 
and rosiglitazone as alternative pharmacotherapies for those who cannot tolerate 
metformin as a result of gastrointestinal side effects .These treatments have resulted in 
beneficial changes in PCOS phenotype with increased menstrual and ovulatory frequency, 
pregnancy and decreased hirsutism. On the other hand, an increase in obstetrical 
pathology in women with PCOS has been documented, including increased rates of 
miscarriage, gestational diabetes, macrosomia, caesarean deliveries and pre-eclampsia. 
Given that hyperinsulinaemia may play a role in the pathophysiology of these conditions, 
maintenance of oral antidiabetic agents during pregnancy may decrease the incidence of 
these complications. Metformin, with a high safety profile for use during pregnancy, has 
been given to pregnant women with PCOS resulting in a reduction of the aforementioned 
conditions in these patients.  
 
Fig. 1. Postulated role for insulin sensitizing agents on target tissues affected in woman with 
PCOS Harborne L etal  
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These concepts have quickly become the cornerstone of diagnosis and treatment of PCOS 
and other diseases also associated with insulin resistance. Type 2 diabetes mellitus and 
gestational diabetes. Recent observations regarding the effect of insulin-sensitizing drugs on 
ovarian stimulation in patients with PCOS undergoing IVF are also discussed, as well as the 
current status of the use of insulin-sensitizing drugs during pregnancy. Finally, substantial 
progress has been made to elucidate the cellular and molecular mechanisms of insulin 
resistance in PCOS. The insulin receptor and genetics of PCOS are complex areas that are 
extensively being investigated. 
These agents increase the tissue sensitivity to insulin action in vivo .The agent commonly 
used in clinical practice is metformin, an oral hypoglycemic biguanide. Newer agents 
include the thiazolidinediones group of drugs like troglitazone. Hepatotoxocity of this drug 
has lead to its withdrawal, but pioglitazone and D-chiroinositol has been used with some 
success in an insulin sensitization in women with PCOS  
3.1 Metformin 
It acts primarily by increasing peripheral glucose uptake in response to insulin at post 
receptor level, with some basal reduction in gluconeogenesis. It improves the insulin 
sensitivity in adipose tissues and skeletal muscles. All of the action are mediated by CAMP 
activated by protein kinase .It has been suggested that various insulin sensitizing drugs 
specifically inhibits the 17 , 20 lyase activity of P450c 17 . While it true that these drugs lower 
the C19 steroids but still the exact mechanism of action of metformin is not clear.  
Until now the use of insulin sensitizing agents are targeted toward symptoms and signs of 
PCOS, like in ovulation induction, as an anti androgen therapy and for hirsutism. In this 
chapter we will be discussing the role of insulin sensitizers particularly metformin in 
prevention of Gestational diabetes associated with PCOS in light of recent evidence support.  
3.2 Use of metformin and prevention and treatment of gestational diabetes mellitus 
Metformin has been used to treat diabetes in second and third trimesters of pregnancy after 
the main teratogenic period, no significant perinatal morbidity and mortality was noticed 
except relatively high frequency of neonatal jaundice. Coetzee et al.14, has published the 
experience of 118 pregnant women with PCOS, who received an oral hypoglycemic 
medication and found the higher frequency of preeclampsia and perinatal mortality. 
However when these study results were critically analyzed it was found these women were 
older, more obese than their reference group which accounted for the baseline 
characteristics rather than Metformin alone.  
The incidence of gestational diabetes in women with PCOS appears to be increased but data 
are not consistent .Insulin resistance in PCOS and the inability of pancreatic beta cells to 
compensate for increased needs of insulin during pregnancy are risk factors for gestational 
diabetes. 
Different studies have documented a decrease in the incidence of gestational diabetes in 
PCOS women treated with metformin during pregnancy. Although in most of them 
retrospective controls were used. Prospective randomized studies with a sufficient number 
of patients are necessary in order to provide good evidence to recommend the use of 
metformin during pregnancy. 
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4. Conclusion 
PCOS is one of the most common hormonal disorder affecting women and has 
reproductive, metabolic, cardiovascular health implications across the life span. Insulin 
resistance in PCOS has been considered as main etiological factor for major health related 
consequences. Significant heterogeneity among studies and dependence of the outcome on 
study type make the higher risk of GDM in women with PCOS a questionable finding. The 
conduction of properly designed studies should precede any recommendation to pregnant 
women with PCOS in regard to the risk of GDM. 
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